GLP-1 Receptor Agonist Research Overview
GLP-1 receptor agonists represent the most significant advance in obesity pharmacotherapy in decades. From semaglutide (single agonist) to tirzepatide (dual) to retatrutide (triple), each generation increases the number of metabolic pathways targeted.
Key Points
Step-by-Step Guide
Understand GLP-1 Biology
GLP-1 (glucagon-like peptide-1) is an incretin hormone released after eating. It stimulates insulin secretion, inhibits glucagon, slows gastric emptying, and promotes satiety via brain signaling. Natural GLP-1 has a 2-minute half-life.
Review Semaglutide Evidence
FDA-approved as Ozempic (diabetes) and Wegovy (obesity). STEP trials: 15-17% body weight loss. SELECT trial: 20% cardiovascular risk reduction. The most clinically validated GLP-1 agonist.
Review Tirzepatide Evidence
FDA-approved as Mounjaro (diabetes) and Zepbound (obesity). Dual GIP/GLP-1 agonist. SURMOUNT trials: 20-22% body weight loss. May surpass semaglutide for weight loss based on trial data.
Explore Next-Generation Agents
Retatrutide: triple agonist (GIP/GLP-1/glucagon), Phase 2 showed 24% weight loss. Orforglipron: oral non-peptide GLP-1 agonist in Phase 3. CagriSema: semaglutide + cagrilintide combination.
Consider Long-Term Implications
Weight regain after discontinuation is significant (most regain 2/3 within a year). Ongoing use may be necessary. Long-term safety data is still accumulating. Muscle mass preservation during rapid weight loss is a concern.
Warnings & Precautions
- !Weight regain is common after stopping GLP-1 agonists.
- !Long-term safety data beyond 2-4 years is limited for newer agents.
- !Muscle mass loss accompanies fat loss—resistance training is important.
- !Compounded/research versions lack FDA quality oversight.
Frequently Asked Questions
Which GLP-1 agonist produces the most weight loss?
Retatrutide (triple agonist) showed 24% in Phase 2. Tirzepatide 15 mg showed 22.5%. Semaglutide 2.4 mg showed 15-17%. Direct comparisons are limited, and Phase 3 data for retatrutide is pending.
Do you have to take GLP-1 agonists forever?
Current evidence suggests weight regain occurs in most people after stopping. Many physicians consider these long-term or indefinite treatments, similar to blood pressure medications. Research into maintenance strategies is ongoing.
What about oral GLP-1 agonists?
Oral semaglutide (Rybelsus) is FDA-approved for diabetes at 14 mg daily. Orforglipron is a promising oral non-peptide GLP-1 agonist in Phase 3 trials that could dramatically expand access.